Core D: Biomarker and Bio-Informatics Core

点击翻译按钮获取中文摘要

CORE D – Abstract The overall aim of Core D is to provide correlative biomarker analyses (including bioinformatics analysis) of primary specimens in the MPN-RC tissue bank, samples arising from all MPN-RC clinical trials, experiments in Projects 1-3, and prospective tissue banking efforts. Core D will carry out assessment of somatic genomic alterations on all MPN-RC samples derived from tissue banking efforts, and from therapeutic trials at baseline and the time of response assessment. The core will also carry out dynamic analyses of other mechanism- based biomarkers (such as serum cytokines, single-cell DNA and RNA sequencing studies, cytogenetics, and histopathology) which pertain to each of the biologic and clinical studies in Projects 1-3. The use of genomic profiling will provide Projects 1-3 with the ability to select genetically annotated samples for biologic studies aimed at investigating the relationship between somatic mutations, biological features of disease pathogenesis, and therapeutic dependencies. The core will also carry out dynamic analyses of mechanism-based biomarkers which pertain to each of the biologic and clinical studies in Projects 1-4. The goal of these assays is to provide comprehensive genetic and biologic correlative studies as well as to help determine the mechanistic impact, and the ability to deplete Myelofibrosis (MF) stem cells, of these hypothesis-driven therapeutic interventions. The proposed analyses will result in integrated genomic, gene expression, and cytokine data of a large number of clinically annotated and homogenously treated patients. As well, the clinical trials proposed in Project 4 are mechanistically based, and stem from work in Projects 1-3. The correlative biomarker assays are directly related to the proposed mechanisms of action of the therapeutic agents which will be investigated in Project 4. These studies will allow for an assessment of the mechanistic impact of specific therapeutic interventions and allow us to credential novel therapeutic targets and pathways. In addition, this will allow biological assessment of treatment responders and non-responders, thus giving insight into mechanisms of resistance. Importantly, we have developed rigorous organizational tools in order to maintain data integrity, traceability and reproducibility standards when dealing with the amount and the variety of data involved in the large-scale biomarker analyses for this core. The integration of state-of-the-art and novel biomarker assays offered by Core D, with robust preclinical and clinical studies will afford a unique opportunity to gain new genomic and biologic insights into MPN pathogenesis.